# A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

Study · id `cardio:ct-nct04671771` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04671771](<https://clinicaltrials.gov/study/NCT04671771>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04671771

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 133 participants.

## Technical summary

Registry record NCT04671771. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-03 (actual); primary completion 2030-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 133 participants (planned count; ClinicalTrials.gov record NCT04671771, source copy `cardio:ctgov-nct04671771-2026-11-09`, retrieved 2026-11-18)
- Started: 2020-12-03 (actual) (ClinicalTrials.gov record NCT04671771, source copy `cardio:ctgov-nct04671771-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2030-03-01 (anticipated) (ClinicalTrials.gov record NCT04671771, source copy `cardio:ctgov-nct04671771-2026-11-09`, retrieved 2026-11-18)
- Completion: 2031-09-01 (anticipated) (ClinicalTrials.gov record NCT04671771, source copy `cardio:ctgov-nct04671771-2026-11-09`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT04671771, source copy `cardio:ctgov-nct04671771-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04671771-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- Condition: End Stage Renal Disease (ESRD)
- Condition: Kidney Failure
- Condition: Chronic Renal Disease
- Condition: Hemodialysis
- Intervention (Device): InnAVasc Arteriovenous Graft (IG) surgical implant
- Lead sponsor: W.L.Gore & Associates
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: W.L.Gore & Associates (`cardio:org-w-l-gore-associates`)

## Provenance

Content hash: 8487ed2866c72b0cd4cac91f0263f08965f9ba98a8c6b605bf8223a585bec035
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
